These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1487614)

  • 1. Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat.
    Zimmermann H; Reichen J
    J Hepatol; 1992 Nov; 16(3):355-9. PubMed ID: 1487614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholate-induced hypercholeresis in cirrhotic rats: further evidence for cholehepatic shunting.
    Elsing C; Sägesser H; Reichen J
    Hepatology; 1994 Oct; 20(4 Pt 1):1048-54. PubMed ID: 7927207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit.
    Cohen BI; Hofmann AF; Mosbach EH; Stenger RJ; Rothschild MA; Hagey LR; Yoon YB
    Gastroenterology; 1986 Jul; 91(1):189-97. PubMed ID: 3710068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
    Luketic VA; Sanyal AJ
    Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ursodeoxycholate and its conjugates on biliary glutathione excretion in rats.
    Takikawa H; Sano N; Yamanaka M
    Dig Dis Sci; 1996 Oct; 41(10):1953-8. PubMed ID: 8888706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile salt-induced cytotoxicity and ursodeoxycholate cytoprotection: in-vitro study in perifused rat hepatocytes.
    Pazzi P; Puviani AC; Dalla Libera M; Guerra G; Ricci D; Gullini S; Ottolenghi C
    Eur J Gastroenterol Hepatol; 1997 Jul; 9(7):703-9. PubMed ID: 9262981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis.
    Invernizzi P; Setchell KD; Crosignani A; Battezzati PM; Larghi A; O'Connell NC; Podda M
    Hepatology; 1999 Feb; 29(2):320-7. PubMed ID: 9918905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholate in primary biliary cirrhosis any--different from the rest?
    Janardan SK; Moseley RH
    J Clin Gastroenterol; 1994 Jan; 18(1):2-3. PubMed ID: 8113579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes.
    Heuman DM; Pandak WM; Hylemon PB; Vlahcevic ZR
    Hepatology; 1991 Nov; 14(5):920-6. PubMed ID: 1937396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
    Botla R; Spivey JR; Aguilar H; Bronk SF; Gores GJ
    J Pharmacol Exp Ther; 1995 Feb; 272(2):930-8. PubMed ID: 7853211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of development on the functional and histological changes induced by bile-duct ligation in the rat.
    Zimmermann H; Blaser H; Zimmermann A; Reichen J
    J Hepatol; 1994 Feb; 20(2):231-9. PubMed ID: 8006404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliary retention in a chronic choledocho-venous fistula in the rat: induction of portal hypertension but not of biliary cirrhosis.
    Zimmermann H; Reichen J; Sägesser H; Tenisch B; Zimmermann A
    J Hepatol; 1993 Aug; 19(1):110-6. PubMed ID: 8301031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
    Güldütuna S; Leuschner U; Imhof M; Zimmer G
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.
    Mazzella G; Parini P; Bazzoli F; Villanova N; Festi D; Aldini R; Roda A; Cipolla A; Polimeni C; Tonelli D
    Dig Dis Sci; 1993 May; 38(5):896-902. PubMed ID: 8482188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of ursodeoxycholate and its taurine conjugate on biliary transport maximum of bilirubin in the rat.
    Sánchez Pozzi EJ; Mottino AD; Sisti A; Roma MG
    Life Sci; 1995; 57(10):973-81. PubMed ID: 7643722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
    Arrese M; Accatino L
    Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver.
    Benedetti A; Alvaro D; Bassotti C; Gigliozzi A; Ferretti G; La Rosa T; Di Sario A; Baiocchi L; Jezequel AM
    Hepatology; 1997 Jul; 26(1):9-21. PubMed ID: 9214446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: role in prevention of estrogen-induced cholestasis.
    Sánchez Pozzi EJ; Crocenzi FA; Pellegrino JM; Catania VA; Luquita MG; Roma MG; Rodríguez Garay EA; Mottino AD
    J Pharmacol Exp Ther; 2003 Jul; 306(1):279-86. PubMed ID: 12663690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.